109 completed, 25 terminated, 6 unknown, 6 withdrawn. 146 Phase 2, 16 Phase 3, 11 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 146 | Completed 109, Terminated 25, Unknown 6, Withdrawn 6 |
| Phase 3 | 16 | Completed 9, Terminated 3, Unknown 3, Withdrawn 1 |
| Phase 1 | 11 | Completed 11 |
Follow Allergan: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV Cenicriviroc Mesylate (CVC), Placebo - HIV Infections | Phase 2 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-11-22 | 2022-12-21 | |
| Investigation of Eluxadoline for Diabetic Diarrhea Eluxadoline 100 mg - Diabetic Diarrhea, Diabetes | Phase 2 / Phase 3 | Withdrawn | Temple University | 2022-07-01 | 2023-05-06 | |
| Study of AGN-190584 Eye Drops to Assess Safety and Efficacy in Participants Aged 40-80 Years With Pseudophakic Presbyopia AGN-190584, Vehicle - Presbyopia | Phase 2 | Withdrawn | Allergan | 2022-06-09 | 2022-06-29 | |
| A Study To Assess the Adverse Effects and Change in Condition of OnabotulinumtoxinA X Injection in Adult Participants With Forehead Lines OnabotulinumtoxinA X, Placebo - Forehead Lines | Phase 2 | Completed | Allergan | 124 | 2021-11-29 | 2025-07-16 |
| A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines OnabotulinumtoxinA X, Placebo - Glabellar Lines | Phase 2 | Completed | Allergan | 328 | 2021-10-06 | 2025-09-09 |
| A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines Formulation A: OnabotulinumtoxinA, Formulation B: OnabotulinumtoxinA, Formulation C: OnabotulinumtoxinA - Glabellar Lines | Phase 2 | Completed | Allergan | 92 | 2021-09-01 | 2025-06-27 |
| Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% in a PROSE Device Restasis - Ocular Surface Disease | Phase 1 / Phase 2 | Completed | Boston Sight | 10 | 2021-07-15 | 2025-01-13 |
| Botulinum Toxin Type A for Foot Dystonia-associated Pain in Parkinson's Disease Botulinum toxin type A, Placebo - Dystonia Disorder, Parkinson Disease | Phase 2 / Phase 3 | Unknown | University of Calgary | 40 | 2021-01-12 | 2022-05-17 |
| CHED - Congenital Hereditary Endothelial Dystrophy: New Paradigm Shift in Therapy Using Topical Eye Drops Nepafenac 0.1% Oph Susp, Refresh Tears 0.5% Lubricant Eye Drops - Congenital Hereditary Endothelial Dystrophy of Cornea | Phase 2 | Unknown | L.V. Prasad Eye Institute | 30 | 2020-12-15 | 2021-04-14 |
| Charité Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients Cenicriviroc (CVC), Placebo - Covid19 | Phase 2 | Terminated | Charite University, Berlin, Germany | 45 | 2020-08-25 | 2022-03-29 |
| Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibactam in Neonates and Infants. Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3, Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3 - Gram-negative Bacterial Infection | Phase 2 | Terminated | Pfizer | 48 | 2020-01-14 | 2024-03-26 |
| Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation Linaclotide, Placebo - Functional Constipation | Phase 2 | Completed | Allergan | 35 | 2019-10-14 | 2022-04-26 |
| A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants Armour® Thyroid, Levothyroxine - Hypothyroidism, Thyroid Disease | Phase 2 | Completed | Allergan | 284 | 2019-10-11 | 2024-06-05 |
| AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines AGN-151586, Placebo - Glabellar Lines | Phase 2 | Completed | Allergan | 198 | 2019-09-26 | 2023-07-28 |
| Intra Articular Injection of Botulinum Toxin Versus Corticoids in Gonarthrosis Botulinum Toxin Type A 100U, Botulinum Toxin Type A 200U, Triamcinolone Hexacetonide Inj Susp 20 MG/ML - Joint Diseases, Knee | Phase 2 | Withdrawn | Lille Catholic University | 2019-09-01 | 2025-09-10 | |
| BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence OnabotulinumtoxinA, Normal saline - Masseter Muscle Prominence | Phase 2 | Completed | Allergan | 150 | 2019-05-16 | 2021-04-28 |
| BOTOX® for the Treatment of Platysma Prominence BOTOX® purified neurotoxin complex, Placebo - Platysma Prominence | Phase 2 | Completed | Allergan | 171 | 2019-04-23 | 2023-05-03 |
| Effects of Eluxadoline (Viberzi®) 100 mg Twice Daily on Diarrhea-Associated Fecal Incontinence Eluxadoline 100 mg, Placebo - Fecal Incontinence, Accidental Bowel Leakage | Phase 2 | Withdrawn | University of North Carolina, Chapel Hill | 2019-04-01 | 2019-07-25 | |
| Treatment of Hypertrophic Scars With Intradermal Botox Botox - Hypertrophic Scar | Phase 2 | Unknown | Roy G. Geronemus, M.D. | 20 | 2018-10-01 | 2018-09-26 |
| Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis Tropifexor (LJN452), Cenicriviroc (CVC) - Non-alcoholic Steatohepatitis (NASH) | Phase 2 | Completed | Novartis Pharmaceuticals | 193 | 2018-09-11 | 2022-04-29 |
Showing 20 of 146. Sign in to see all of them.
Macular Degeneration (11) · Ocular Hypertension (11) · Macular Edema (9) · Cystitis, Interstitial (5) · Diabetes Mellitus (5) · Dry Eye Syndromes (5) · Glaucoma (5) · Glaucoma, Open-Angle (5) · Alopecia (4) · Choroidal Neovascularization (4) · Presbyopia (4) · Urinary Bladder, Overactive (4) · Asthma (3) · Migraine Disorders (3) · Muscle Spasticity (3)
Botulinum Toxins, Type A (36) · Dexamethasone (17) · Saline Solution (15) · salicylhydroxamic acid (13) · Bimatoprost (11) · Calcium Dobesilate (11) · Ranibizumab (10) · Brimonidine Tartrate (7) · Cyclosporins (6) · Sodium Chloride (6) · Ophthalmic Solutions (4) · abicipar pegol (4) · Bevacizumab (3) · Botulinum Toxins (2) · Dapsone (2)
United States (119) · Canada (22) · Germany (20) · Australia (16) · United Kingdom (15) · France (12) · Israel (11) · Czechia (9) · India (9) · Italy (9) · Philippines (8) · Poland (8) · South Korea (7) · Portugal (6) · Belgium (5)
Joan-En Lin (3) · Till Geib (3) · Curtis Nickel, MD (2) · Haixia Liu (2) · Steven Garrett, MS, DDS (2) · Aida Lugo-Somolinos, MD (1) · Ammar Hatab, MD (1) · Andrew Travlos, MD (1) · Anna Muslin (1) · Armen Mashayekhi, MD (1) · Arthur James Moser, MD (1) · Benjamin Sucher, DO (1)
PMID 32134802, PMID 34288094, PMID 39982105, PMID 16651948, PMID 16901024, PMID 17173593, PMID 17177750, PMID 17353400, PMID 19268890, PMID 19289689, PMID 19357910, PMID 19802513, PMID 20212194, PMID 20212197, PMID 20346780, PMID 20609706, PMID 21220619, PMID 22464310, PMID 23098762, PMID 23411886, PMID 23761087, PMID 28760384, PMID 29127949, PMID 29753118, PMID 30293228, PMID 30688903, PMID 31609787, PMID 31731005, PMID 32301137, PMID 32822633, PMID 33206392, PMID 33383315, PMID 33666272, PMID 34643894, PMID 34855038, PMID 35643967, PMID 38462625, PMID 38640068, PMID 38962910, PMID 39648629, PMID 40251980, PMID 40704633, PMID 41933889, PMID 42753227
2014 (2), 2017 (1), 2018 (1), 2019 (1)